Search the Newsreel

Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain

Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

Tempest Therapeutics announced a collaboration with Senlang Biotechnology to advance its TPST-4003 in vivo CAR-T product candidates, targeting first patient dosing in late 2026 and initial clinical data in early 2027. The company also appointed Drake Richey and Dr. John Yee to its Board …

Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Tempest Therapeutics Inc is projected to report a loss of 30 cents per share. This earnings preview indicates the company's financial performance expectation. The full article is available through TradingView, providing access to Reuters news.

Tempest Therapeutics Market Sentiment

This article analyzes the market sentiment for Tempest Therapeutics (TPST) based on analyst consensus, short interest, options flow, and insider activity. Analysts currently have a "Buy" consensus with an average price target significantly higher than the current share price, despite recent downgrades from some …

TPST|Tempest Therapeutics Inc|Price:0.856|Chg%:-0.007

This analysis of Tempest Therapeutics Inc (TPST) highlights its healthy fundamentals and high growth potential, though its valuation is considered fairly valued within the Biotechnology & Medical Research industry. The company has high institutional ownership and multiple "Buy" ratings from analysts, despite a weak …

Tempest Therapeutics Adjourns Vote on Governance Changes

Tempest Therapeutics adjourned a special stockholder meeting aimed at approving an amendment to its Restated Certificate of Incorporation to eliminate supermajority voting requirements and allow stockholder action by written consent. Although a quorum was met, the proposal did not secure the required 75% approval. …

Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Tempest Therapeutics Inc (TPST), detailing its volatility, financial risks, and investment risks. TPST currently has a risk assessment score of 1.53, ranking 288 out of 384 in the Biotechnology & Medical Research industry, with a beta of …

Tempest Therapeutics Inc (TPST) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Tempest Therapeutics Inc.'s (TPST) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The article also lists several stock merger events with corresponding ratios, including one scheduled …

Tempest Therapeutics Inc (TPST) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Tempest Therapeutics Inc (TPST)'s financial health, indicating a current score of 6.98, which ranks it 163 out of 384 in the Biotechnology & Medical Research industry. While its financial status is robust, its operating efficiency is low. The …

Tempest Therapeutics Inc (TPST) Cash Flow

This article provides a comprehensive overview of Tempest Therapeutics Inc.'s (TPST) cash flow statement, including quarterly and annual data for operating, investing, and financing activities. It details specific financial figures, year-over-year changes, and definitions of key cash flow metrics like operating cash flow, investing …

Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tempest Therapeutics Inc (TPST), outlining major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in shares held and proportion.

Tempest Therapeutics Inc (TPST) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Tempest Therapeutics Inc (TPST). It provides a current score and lists significant institutional shareholders, detailing their shareholdings and recent changes in their positions. Key shareholders include Angel (Matthew), Lotus Capital Limited, and Versant Ventures, …

Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST

TPST|Tempest Therapeutics Inc|Price:0.930|

Tempest Therapeutics Inc (TPST) is a clinical-stage biotechnology company with a current share price of $0.940 and a market cap of $13.49M. Analysts rate the stock as "Buy" with a target price of $11.00, indicating significant upside potential despite recent poor stock performance. The …

Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases

Tempest Therapeutics has partnered with Hebei Senlang Biotechnology to advance its in vivo CAR-T candidate, TPST-4003, for neurological autoimmune diseases. A first-in-human trial in China, involving approximately 10 patients with conditions like myasthenia gravis and multiple sclerosis, is expected to begin dosing in Q4 …

Tempest Announces Development Collaboration with Senlang

Tempest Therapeutics has announced a development collaboration with Senlang Biotechnology for its proprietary TPST-4003, a CD7-targeted next-generation in vivo CAR-T candidate. The partnership will initiate a first-in-human investigator-initiated trial in China for patients with neurological autoimmune diseases like myasthenia gravis and multiple sclerosis, with …

Tempest Therapeutics (TPST) plans vote on supermajority and written-consent changes

Tempest Therapeutics will hold a virtual Special Meeting on July 27, 2026, to vote on amending its Restated Certificate of Incorporation. The proposed changes aim to permit stockholder action by written consent and replace certain existing supermajority voting requirements with a majority-of-outstanding standard, aligning …

Tempest Therapeutics (TPST) Edges Lower as Stock Hovers Near Key Support Level - SuperTrend Flip

TPST Q1 2026 Earnings: EPS Misses Estimates Sharply as Clinical-Stage Biotech Posts No Revenue - Analyst Drop Coverage

Tempest Therapeutics (TPST) Earnings Date and Reports 2026 $TPST

Should I buy Tempest Therapeutics (TPST)

Tempest Therapeutics (TPST) Stock Price, News & Analysis

Tempest Therapeutics Inc (TPST) Earnings, Actual EPS, EPS Estimates & Results

What is the current Price Target and Forecast for Tempest Therapeutics (TPST)

Tempest Therapeutics (TPST) Stock Price, News & Analysis $TPST